isosorbide has been researched along with salicylates in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Haen, P | 1 |
| Carolan, CG; Dillon, GP; Gaynor, JM; Gilmer, JF; Holland, V; Jones, M; Khan, D; Marquez, JF; Reidy, S; Ryder, SA | 1 |
| Cefali, G; Gilmer, JF; Harmon, S; Jones, M; Kerins, DM; Ledwidge, MT; O'Connell, D; Ryan, F | 1 |
3 other study(ies) available for isosorbide and salicylates
| Article | Year |
|---|---|
Drugs released for clinical use.
Topics: Analgesics; Anti-Inflammatory Agents; Antitussive Agents; Betamethasone; Cimetidine; Colestipol; Dihydroergotoxine; Diphenhydramine; Drug Therapy; Furosemide; Humans; Isosorbide; Oxycodone; Pharmaceutical Preparations; Salicylates; United States; United States Food and Drug Administration; Vitamins | 1978 |
Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor.
Topics: Anions; Binding Sites; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Humans; Inhibitory Concentration 50; Intestines; Isosorbide; Male; Microsomes, Liver; Models, Molecular; Molecular Structure; Mutation; Salicylates; Structure-Activity Relationship | 2010 |
In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?
Topics: Animals; Apolipoproteins B; Aspirin; Blood Glucose; Chemistry, Pharmaceutical; Cholesterol, LDL; Cyclooxygenase Inhibitors; Hyperglycemia; Hypolipidemic Agents; Isosorbide; Lipid Metabolism; Lipids; Macaca fascicularis; Models, Biological; Niacin; Postprandial Period; Prodrugs; Prostaglandin D2; Salicylates; Thromboxane B2; Triglycerides | 2012 |